Careteq Ltd. (CTQ) AI Stock Analysis

• Market Cap: N/A
• Dividend Yield: N/A
• Average Volume (3M): 177.00K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.41
• Revenue Growth: -2.77%
• EPS Growth: 65.63%
• Country: AU
• Employees: 24
• Sector: Healthcare
• Sector Strength: 40
• Industry: Medical - Healthcare Information Services
• EPS (TTM): 0.00
• Shares Outstanding: 237,118,710
• 10 Day Avg. Volume: 68,499
• 30 Day Avg. Volume: 177,001
• PEG Ratio: -0.16
• Price to Book (P/B): 5.21
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.10
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 45 Neutral
• Price Target: AU$0.00 ▼(-100.00%Downside)

The overall stock score is primarily influenced by financial performance and valuation challenges. Despite strong revenue growth, persistent profitability issues weigh heavily on the score. Technical analysis suggests potential for a rebound but is currently bearish. The lack of earnings call and corporate events data further emphasize existing weaknesses in financial health and valuation.

Careteq Ltd. Business Overview & Revenue Model

Company Description

Careteq Limited, a health-tech company, provides software as a service (SaaS)-based assistive living technology and services that focuses on meeting the needs in the health, aged, and home care sectors worldwide. The company develops and commercializes a suite of products that sit on its proprietary SaaS based assistive living technology platform for use by the elderly, disabled, and vulnerable individuals. It also offers medication management services, which include expert geriatric clinical pharmacy decision support services to general practitioners. The company was founded in 2016 and is based in Melbourne, Australia.

How the Company Makes Money

Careteq Ltd. generates revenue primarily through the sale and subscription of its digital health products and services. The company offers smart monitoring devices and telehealth services to individual customers, healthcare facilities, and aged care providers. Careteq also earns income through licensing its integrated software platforms, which are designed to facilitate remote monitoring and data analytics for healthcare professionals. Strategic partnerships with healthcare institutions and technology companies further bolster its revenue streams by expanding its market reach and enhancing product offerings. Additionally, the company may receive funding or grants from government bodies or private investors to support its innovation and development initiatives.

Careteq Ltd. Financial Statement Overview

Summary

Careteq Ltd. is experiencing strong revenue growth, which is a positive sign for future potential. However, the company continues to face challenges with profitability, as evidenced by negative margins and net income. The balance sheet shows low leverage but declining equity, while cash flow statements highlight ongoing cash constraints. Overall, the company needs to improve operational efficiency and manage cash flows more effectively to achieve sustainable growth and profitability.

Income Statement

The company has shown significant revenue growth, with a 30.9% increase from 2023 to 2024. However, profitability remains a concern with negative net and gross profit margins. The net income margin is consistently negative, indicating ongoing losses. Despite an improvement in revenue, the company's EBIT and EBITDA margins are negative, reflecting challenges in operational efficiency and profitability.

Balance Sheet

The balance sheet shows a moderate debt-to-equity ratio with low total debt, which suggests limited leverage and potential stability. However, the company's equity has decreased over time, reducing the equity ratio. The return on equity is negative due to net losses, indicating that the company is not generating profits from shareholders' equity.

Cash Flow

The company is facing negative free cash flow, although there is a slight improvement in operating cash flow compared to the previous year. The free cash flow to net income ratio is unfavorable, indicating cash flow challenges. The financing cash flow is positive, suggesting reliance on external funding to support operations.

Breakdown	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement
Total Revenue	7.23M	5.52M	4.43M	735.44K	146.46K
Gross Profit	6.74M	-2.44M	4.14M	-2.03M	-1.33M
EBITDA	-826.62K	-3.57M	-5.90M	-5.06M	-1.93M
Net Income	-2.67M	-4.33M	-5.25M	-5.23M	-1.91M
Balance Sheet
Total Assets	6.82M	7.57M	8.02M	12.23M	926.87K
Cash, Cash Equivalents and Short-Term Investments	1.25M	1.85M	4.50M	8.90M	202.05K
Total Debt	192.98K	961.96K	0.00	75.28K	0.00
Total Liabilities	3.30M	4.02M	1.72M	2.61M	4.67M
Stockholders Equity	1.97M	2.14M	6.30M	9.61M	-3.74M
Cash Flow
Free Cash Flow	-2.59M	-3.42M	-4.54M	-1.52M	-1.33M
Operating Cash Flow	-1.30M	-2.53M	-4.52M	-1.50M	-1.32M
Investing Cash Flow	-570.80K	-799.63K	-256.83K	-23.21K	-11.55K
Financing Cash Flow	1.27M	687.55K	8.81M	1.50M	1.23M

Careteq Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.01
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:CTQ, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.01, below the 50-day MA of 0.01, and below the 200-day MA of 0.01, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 36.48 is Neutral, neither overbought nor oversold. The STOCH value of <0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:CTQ.

Careteq Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MDR	62 Neutral	AU$46.89M	110.00	-8.34%	―	-5.27%	50.29%
PCK	55 Neutral	AU$71.84M	―	-457.46%	―	21.93%	10.34%
Sector *	52 Neutral	$7.37B	-0.04	-63.81%	2.59%	16.40%	<0.01%
SHG	48 Neutral	AU$102.58M	―		―	―	―
CTQ	45 Neutral		―	-39.44%	―	-2.77%	65.63%
GLH	44 Neutral	AU$4.39M	―		―	-11.00%	86.56%
ICR	34 Underperform	AU$6.83M	―	-309.52%	―	73.53%	-7.35%

Careteq Ltd. Corporate Events

Careteq Limited Announces Director’s Interest Change

Careteq Limited has announced a change in the director’s interest notice, specifically regarding Mark Simari. The company disclosed that 3,000,000 unlisted options held indirectly by Simari through Charkaroo Pty Ltd have expired, with no new acquisitions or disposals of other securities reported. This change signifies a reduction in potential future equity for the director, which may impact his financial stake in the company.

Careteq Ltd. Issues Unlisted Convertible Notes

Careteq Ltd. announced the issuance of 355,678 unlisted convertible notes, marking a strategic financial move to potentially enhance its capital structure. This issuance is expected to impact the company’s financial flexibility and could influence its market positioning by providing additional resources for growth and development.

Careteq Limited Addresses Breach of ASX Listing Rule with Remedial Actions

Careteq Limited has acknowledged a breach of ASX Listing Rule 7.1 due to an incorrect issuance of convertible notes, exceeding its placement capacity. The company has taken remedial actions by amending the agreement and will seek shareholder approval for the excess issuance, reaffirming its commitment to compliance and corporate governance.

Careteq Limited Secures $625,000 in Funding to Strengthen Financial Position

Careteq Limited has secured a $500,000 convertible note from investor and entrepreneur Antanas Guoga to bolster its working capital. Additionally, the company’s board members have contributed $125,000 through a loan agreement, bringing the total raised to $625,000. This funding positions Careteq well for medium-term financial stability and reflects confidence in its strategic direction and market potential.

Careteq Disputes ATO’s Amended R&D Tax Assessments

Careteq Limited has received amended assessments from the Australian Taxation Office regarding its R&D Tax Incentive claims for the financial years ending in 2021, 2022, and 2023, requiring repayment of refunds and interest. The company disputes these assessments and plans to formally object, maintaining confidence in the eligibility of its R&D activities and the validity of its claims, and will engage with the ATO throughout the objection process.

Careteq Ltd. Announces Cessation of Securities

Careteq Ltd. announced the cessation of 2,000,000 securities due to the expiry of options or other convertible securities without exercise or conversion as of May 6, 2025. This cessation of securities may impact the company’s capital structure and could have implications for its financial strategies and stakeholder interests.

Careteq Limited Reports Strong Q3 FY25 Performance and Strategic Growth

Careteq Limited has reported significant progress in its Q3 FY25 activities, with the integration of its 1-System platform nearing completion, which is expected to enhance operational efficiencies and profitability. The company has exceeded revenue growth projections while reducing overhead costs, and it maintains a positive EBITDA. Strategic partnerships, such as with Medic Alert, have expanded Careteq’s market reach, particularly in aged care and GP networks, positioning the company for sustainable growth and shareholder value.